SanegeneBio has struck a $1.5bn global licensing deal with Genentech, granting exclusive rights to a selected RNAi programme. SanegeneBio will handle early development, while Genentech will manage clinical development and global commercialization. The collaboration focuses on SanegeneBio’s RNAi platform with new chemistries and delivery technologies for siRNA medicines.

The agreement includes a $200m upfront payment to SanegeneBio, with potential milestone payments of up to $1.5bn and royalties based on future sales. SanegeneBio’s CEO, Weimin Wang, views the deal as a significant step for their RNAi chemistry and delivery platforms, aiming to deliver innovative therapies worldwide.

SanegeneBio, a venture-backed biotech firm, focuses on advancing RNAi-based therapeutics with R&D locations in Shanghai, Suzhou, and Boston. Their pipeline includes experimental medicines targeting cardiometabolic indications, obesity, and autoimmune nephropathies, with ongoing clinical trials utilizing their LEAD tissue-selective RNAi delivery technology.

In November 2025, SanegeneBio entered a research and licensing partnership with Eli Lilly and Company for RNAi candidates targeting metabolic diseases. The company’s collaboration with Genentech is another milestone in advancing RNAi therapeutics for various medical conditions.

Read more at Yahoo Finance: SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal